Search

everythinglearnresearchcommunity

for

Search:↓

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Abatacept may help some people with alopecia areata regrow hair.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Methotrexate plus prednisolone had the fewest serious side effects.

The treatment was effective for advanced non-Hodgkin's lymphomas.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Tofacitinib may help treat nail dystrophy, especially when other treatments fail.

Hormone-replacement therapy improved a woman's skin condition known as lymphomatoid papulosis.

Ocrelizumab may cause pancreatitis in some patients.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

Combining tacrolimus with excimer light is more effective for treating alopecia areata than using excimer light alone.

Topical Ruxolitinib may safely treat severe hair loss.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Ritlecitinib helps hair regrowth and reduces emotional and functional burdens in alopecia areata.